Business Context and Reporting Period
Company: Genprex, Inc. (GNPX)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Genprex is a clinical-stage gene therapy company developing treatments for cancer and diabetes. Its lead oncology candidate, REQORSA (quaratusugene ozeplasmid), utilizes a non-viral delivery system to express the TUSC2 tumor suppressor gene. The company is also developing GPX-002, a gene therapy for Type 1 and Type 2 diabetes.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(21.1) million | $(30.9) million |
| Operating Expenses | $21.2 million | $31.1 million |
| Cash and Cash Equivalents (Year-End) | $1.6 million | $6.7 million |
| Accumulated Deficit | $(154.8) million | $(133.7) million |
| Net Cash Used in Operating Activities | $(17.1) million | $(24.7) million |
| Net Cash Provided by Financing Activities | $12.0 million | $10.6 million |
Note: The company has no debt obligations as of December 31, 2024.
Material Changes vs. Prior Period
- Reduced Net Loss: Net loss decreased by approximately 32% (from $30.9 million to $21.1 million) primarily due to expense reduction strategies, including reduced headcount (from 28 to 16 employees), lower travel expenses, and reduced professional service fees.
- Research & Development (R&D) Expenses: Decreased by 40% to $10.5 million, driven by changes in Contract Development and Manufacturing Organizations (CDMOs) that reduced manufacturing costs and a reduction in share-based compensation.
- General & Administrative (G&A) Expenses: Decreased by 21% to $10.6 million, despite one-time charges related to executive separation and accounting policy adjustments.
- Capital Structure: The company completed a 1-for-40 reverse stock split effective February 2, 2024. All share data in the filing has been adjusted retroactively.
Guidance, Outlook, and Management Commentary
Clinical Pipeline Updates
- Acclaim-1 (NSCLC): Enrolling in the Phase 2a expansion of REQORSA combined with Tagrisso. The protocol was amended in February 2025 to allow patients who progressed on Tagrisso-containing regimens. Interim analysis is expected in the first half of 2026.
- Acclaim-2 (NSCLC): Enrollment ceased in August 2024 due to slow enrollment and competition for patients. The trial is closed.
- Acclaim-3 (SCLC): Phase 1 dose escalation completed in December 2024 with no dose-limiting toxicities. Phase 2 expansion is enrolling patients receiving REQORSA and Tecentriq. Interim analysis expected in the second half of 2025.
- Diabetes (GPX-002): Preclinical studies are ongoing. The company plans to seek FDA guidance on IND-enabling studies in the second half of 2025.
Strategic Reorganization
On February 18, 2025, the company formed a wholly-owned subsidiary, Convergen Biotech, Inc., to house the diabetes clinical development program and assets. Genprex will retain its oncology programs.
Liquidity and Going Concern
Management has raised substantial doubt regarding the company's ability to continue as a going concern. As of December 31, 2024, cash was $1.6 million. Management estimates current resources will fund operations only into the second quarter of 2025. Additional capital is required to continue clinical trials and operations.
Recent Financing
Subsequent to year-end (January 1, 2025, through filing date), the company raised approximately $6.0 million through its At-The-Market (ATM) offering program.
Risks and Contingencies
- Nasdaq Compliance: The company received notices of non-compliance with Nasdaq minimum stockholders' equity and minimum bid price requirements. Extensions were granted until March 31, 2025, and August 6, 2025, respectively, contingent on raising capital.
- Internal Controls: The company identified material weaknesses in internal controls over financial reporting due to a lack of segregation of duties and insufficient accounting personnel depth.
- Leadership Change: Former CEO and Chairman J. Rodney Varner passed away in May 2024. Ryan M. Confer assumed the roles of President, CEO, and CFO.
Key Facts for Investor Verification
- Cash Runway: Verify the sufficiency of the $6.0 million raised post-year-end to extend the runway beyond Q2 2025 and meet Nasdaq compliance milestones.
- Acclaim-1 Enrollment: Monitor the progress of patient enrollment in the Acclaim-1 Phase 2a expansion, specifically the impact of the protocol amendment allowing Tagrisso-containing regimen patients.
- Internal Control Remediation: Review the status of remediation efforts for the material weaknesses in internal controls over financial reporting.
- Convergen Spin-off: Track the progress of transferring the diabetes program to the new subsidiary, Convergen Biotech, Inc.
- CDMO Relationships: Confirm the stability of manufacturing supply chains following the termination of a previous CDMO agreement in 2024.